A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease
Latest Information Update: 01 Jan 2025
Price :
$35 *
At a glance
- Drugs Evolocumab (Primary) ; HMG-CoA reductase inhibitors
- Indications Atherosclerosis; Cardiovascular disorders; Hyperlipidaemia; Myocardial infarction; Stroke
- Focus Registrational; Therapeutic Use
- Acronyms FOURIER; PROFICIO
- Sponsors Amgen
- 18 Nov 2024 Results discussing Association Between Lipoprotein(a) Levels and Incident Complex Coronary Revascularization Procedures , presented at the American Heart Association Scientific Sessions 2024
- 18 Nov 2024 Results studying Changes in high-sensitivity cardiac troponin I and associated cardiovascular risk, presented at the American Heart Association Scientific Sessions 2024
- 08 Apr 2024 Results from FOURIER and FOURIER OLE assessing Long-Term Efficacy of Evolocumab in Patients With and Without Multivessel Coronary Artery Disease, presented at the 73rd Annual Scientific Session of the American College of Cardiology